Randomized Trial: Among Patients with MRSA Bacteremia, the Addition of an Antistaphylococcal β-lactam to Standard Therapy Does Not Improve Outcomes

Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Combination Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: Not Ready for Prime Time (free for a limited period)

Commentaries: Trial pours cold water on combo treatment for MRSA bacteremia – CIDRAP (free) AND Trial shows using two drugs not better than one when treating MRSA blood infections – University of Melbourne (free)

Related Commentary on Twitter

Adding an antistaphylococcal β-lactam to standard #antibiotic therapy w vancomycin or daptomycin did not improve a primary composite outcome of mortality, persistent #bacteremia, relapse, or Tx failure in pts with #MRSA bacteremia https://t.co/UpyCz3Ss4F #VisualAbstract

— JAMA (@JAMA_current) February 12, 2020